Skip to content

New Mexico Honey Wound Treatment Research Study

New Mexico Honey Wound Treatment Research Study

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01748318
Enrollment
60
Registered
2012-12-12
Start date
2013-03-31
Completion date
2018-07-31
Last updated
2016-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired Methicillin-resistant Staphylococcus Aureus Infection

Keywords

Community acquired MRSA, New Mexico Honey

Brief summary

In a time of emerging bacteria that are resistant to antibiotics, honey offers an alternative that has potential to reduce the heavy reliance on pharmaceutical antibiotics. We will be evaluating the effectiveness of a locally produced New Mexico Honey against the standard of care Bactrim antibiotic on Community Acquired MRSA.

Detailed description

Locally grown New Mexico Honey will be utilized on abscess wounds of the trunk and extremities vs routine (Bactrim) antibiotic care to determine if NM Honey is effective treatment for Community Acquired MRSA 6 cm abscesses.

Interventions

DRUGNew Mexico Honey

Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment

Bactrim DS

Sponsors

R. Stephen Rankin, M.D.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients 16 years of age or older * Abscess less than or equal to 6 cm in diameter on the extremity or trunk requiring incision and drainage * Patient willing to try honey prepared dressing * Patient able to return to office each day for 7 days for evaluation

Exclusion criteria

* Under the age of 16 * Abscess of face, scalp or genitals * Diagnosed as a diabetic * Allergic to bee pollen, honey or sulfa antibiotics * Diagnosed with peripheral vascular disease * Patient acknowledgement of current drug or alcohol abuse

Design outcomes

Primary

MeasureTime frameDescription
Size of lesion at day 77 daysIncrease in size will determine failure; Decrease in size will determine success

Countries

United States

Contacts

Primary ContactR Stephen Rankin, MD
rstephen_rankin@msn.com505 324 1000
Backup ContactJoseph Pope, MD
jpope10@msn.com505 324 1000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026